|View printer-friendly version|
The new GeneCards® release includes more than 94,500 gene entries. One of the important enhancements is the display of about 52,000 non-protein-coding RNA genes, more than tripling the previous count, thus affording a new vista of this ground-breaking category of human genes. A second novel feature is a vast expansion of the mutual similarity space for human genes, employing powerful gene sequence alignments. GeneCards® now also shows considerably expanded tissue proteome abundance diagrams. Further, the pathways section has been expanded to six data sources, thus allowing a much better view of cellular gene networks. Further enhancements include a better disease section, more finely-tuned advanced search and batch query (GeneALaCart) and new gene-related research reagents, including human, mouse and rat products from a variety of providers.
Separately, LifeMap Sciences has recently announced that it has entered into a license agreement with
GeneCards® (http://www.genecards.org/) is a searchable, integrated database of human genes that provides concise genomic, transcriptomic, genetic, proteomic, functional, and disease-related information on all known and predicted human genes. Information is featured in 20 GeneCards sections and includes orthologies, disease relationships, mutations and SNPs, gene expression, gene function, pathways, protein-protein interactions, related drugs and compounds and direct links to valuable research products such as antibodies, recombinant proteins, nucleic acids, expression assays, and RNAi-related products. GeneCards® was developed over the last 15 years by a world-leading bioinformatics team led by Professor
LifeMap Sciences’ (www.lifemapsc.com) core technology and business is based on its integrated database suite, The go-to discovery and marketing platform for biomedical and stem-cell research. This platform will include GeneCards®: the leading human gene database; the LifeMap™ database of embryonic development, stem cell research and regenerative medicine; and MalaCards, the human disease database. LifeMap Sciences also markets PanDaTox, a recently developed, searchable database that can aid in the discovery of new antibiotics and biotechnologically beneficial products.
In addition to database offerings,
In a therapeutic discovery collaboration with
Statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for
To receive ongoing
Peter Garcia, 510-521-3390 ext. 367
Chief Financial Officer
Judith Segall, 510-521-3390 ext. 301
LifeMap Sciences, Inc.
Kenneth Elsner, 781-826-7719